Phase 1 Results Reported for Anti-LINGO-1 Remyelination Agent
BIIB033, a monoclonal antibody targeting the LINGO-1 remyelination signaling block, passes phase 1 safety tests
BIIB033, a monoclonal antibody targeting the LINGO-1 remyelination signaling block, passes phase 1 safety tests
A high-profile experimental treatment to repair the damaged myelin around nerves in people with...
Clinical Research, Drug Development